Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression Carmen A. Zavala, Ana C. Thomaz, Vishakh Iyer, Ken Mackie, and Andrea G. Hohmann Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 389-400. DOI: 10.1089/can.2020.0059 Abstract Introduction : Overdose fatalities associated with the opioid epidemic are predictably attributable to druginduced respiratory depression. In terms of illicit opioid abuse, fentanyl is the synthetic opioid responsible for the largest number of overdose deaths. There is, therefore, an urgent need to identify safe and effective therapeutics that can attenuate fentanyl-induced respiratory depression. Identification of effective alternate analgesic strategies that lessen the respiratory depression associated with narcotics would also help [...]
Lire la suiteCannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression Beth M. Wiese, Erika Liktor-Busa, Aidan Levine, Sarah A. Couture, Spyros P. Nikas, Lipin Ji, Yingpeng Liu, Kenneth Mackie, Alexandros Makriyannis, Tally M. Largent-Milnes and Todd W. Vanderah Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 401-412. Doi : 10.1089/can.2020.0076 Abstract Introduction : An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBo¨ tzinger complex in the brainstem. Objective : Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance [...]
Lire la suiteEmerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1, 179-189. Doi : 10.1089/can.2018.0022 Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful [...]
Lire la suite